New research indicates that people who come off blockbuster GLP-1 drugs like Wegovy and Mounjaro may regain shed pounds far faster than those who halt traditional diet and exercise programs.
Findings released in a prominent medical journal demonstrates that while obese individuals frequently drop substantial amounts of their body weight while using the jabs, the mass is regained at an average rate of nearly a kilo each month once they quit.
"Users using these medications need to be cognizant of the danger of fast weight regain when the medication is stopped," stated researcher Dr. Susan Jebb.
Such speed of recovery implies a return to pre-treatment mass within about a year and a half.
Analyzing Therapies
The analysis, which examined dozens of studies involving over 9,000 of patients, contrasted the effects of GLP-1 agonists with older methods.
The team emphasize that people who lose weight through dieting usually have a less rapid weight regain—around 100 grams monthly—once they finish.
Explaining the Quick Regain
Nutrition scientists propose the way of the drugs is key to understanding the heightened rebound.
These medications mimic a body's own chemical called GLP-1, which helps regulate appetite.
"Long-term administration of GLP-1 levels far above than the body's typical production could lead to the system to generate a reduced amount of its endogenous GLP-1, and could lessen sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.
"Stopping of this hormone supplement means hunger is unsuppressed, making excessive eating far more likely."
An Ongoing Disease?
Health authorities recommend the injections for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Professionals argue that, considering the likelihood of relapse, the therapy is often ongoing.
This view is echoed by drug manufacturers, who note that the results "highlight the chronic character of excess weight," akin to managing diseases like diabetes.
User Testimonies
People who have discontinued the jabs report a sudden resurgence of cravings.
"I experienced something activating and I was suddenly ravenous," said one woman.
This challenge is exacerbated if individuals have not established sustainable lifestyle or habit changes during therapy.
Significant Use
Figures suggest that a significant number of people in the UK have tried weight-loss jabs in the past year, with desire continuing to grow.
- Adoption is higher among females compared to men.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, researchers emphasize that while the jabs are potent agents for weight loss, they are not a standalone solution and maintained weight loss likely depends on ongoing behavioural management.
